List of Seebri drug patents

Seebri is owned by Novartis.

Seebri contains Glycopyrrolate.

Seebri has a total of 2 drug patents out of which 0 drug patents have expired.

Seebri was authorised for market use on 29 October, 2015.

Seebri is available in powder;inhalation dosage forms.

The generics of Seebri are possible to be released after 20 October, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(5 years from now)

US8182838 NOVARTIS Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Oct, 2028

(5 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 29 October, 2015

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in